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Abstract
One limitation of current biodegradable polymeric nanoparticles is their inability to effectively
encapsulate and sustainably release proteins while maintaining protein bioactivity. Here we report
the engineering of a PLGA-polycation nanoparticle platform with core-shell structure as a robust
vector for the encapsulation and delivery of proteins and peptides. We demonstrate that the
optimized nanoparticles can load high amounts of proteins (>20% of nanoparticles by weight) in
aqueous solution by simple mixing via electrostatic interactions without organic solvents, forming
nanospheres in seconds with diameter <200 nm. We also investigate the relationship between
nanosphere size, surface charge, PLGA-polycation composition, and protein loading. The stable
nanosphere complexes contain multiple PLGA-polycation nanoparticles, surrounded by large
amounts of protein. This study highlights a novel nanoparticle platform and nanotechnology
strategy for the delivery of proteins and other relevant molecules.
Keywords
nanoparticle; PLGA; polycation; protein delivery; structure-function
Since the 1970s, protein therapy has become a promising strategy for the effective treatment
of cancers, diabetes, cardiovascular diseases, and many other disorders.1-6 However, the safe
and effective delivery of proteins to the desired disease locations or intracellular sites
remains a major challenge due to the intrinsic properties of most proteins, such as high
molecular weight (MW), surface charges, and vulnerable tertiary structures.2 Thus specific
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and robust delivery vehicles are needed to facilitate the loading, delivery, and controlled
release of proteins.
Numerous protein carrier platforms have been developed for better therapeutic performance.
For example, microspheres7 and hydrogels3, 8 have been utilized to solve the sustained
release issue. However, these systems have limited applications for intracellular protein
delivery due to their large size. For effective intracellular delivery, other systems including
liposomes,9 polymer conjugates,10 nanotubes,11 nanogels,12 and nanoparticles (NPs)4, 6 are
being extensively investigated. Among them, biodegradable polymeric NPs have aroused
great interest as potentially robust protein carriers due to their biocompatibility,
biodegradability, amenability to formulation, and capability for intracellular and systemic
delivery.2, 13-15 Nevertheless, the major types of proteins and protein analogues are
negatively charged and have complicated, sensitive, and fragile 3-D structures and sizes
ranging from ∼ 2 - 15 nm. Thus the currently available polymeric NP platforms require
further optimization in order to load and encapsulate proteins with high efficiency and
release them in a sustained manner while maintaining their bioactivity.2
For effective protein delivery, the ideal polymeric NP platform should have: (1) high protein
loading (low NP mass to achieve therapeutic dose); (2) “green” protein encapsulation: little
or no organic solvents used to prevent protein denaturation; (3) minimal contact with
carriers to avoid the low local pH caused by polymer degradation;16, 17 (4) sustainable and
controllable protein release with low initial burst. Inspired by the electrostatic interactions
between polyelectrolytes, we hypothesized that a NP system with very strong cationic
moieties may be ideal to load and release a large quantity of proteins in a safe and
controllable manner. A novel protein loading strategy was developed, utilizing very strong
cationic NPs to physically adsorb proteins to form a new NP/protein complex nanosphere
platform in aqueous solution (Figure 1).
To this end, a polymeric NP platform with a cationic shell was first developed from the di-
block copolymer of poly(lactide-co-glycolic acid) (PLGA) and L-arginine-based polycation
(PC) (Figures 1 and 2). PLGA-based NPs have been widely utilized due to their unique
biocompatibility, biodegradability, small particle size, and high drug loading capacity.18-20
During formulation, the hydrophobic PLGA segments form a solid inner core and limit the
NP to a small nanosize, while the hydrophilic and water-soluble PC portion forms the outer
shell, creating a very strong electrical field for protein adsorption (loading). The final goal
was to screen PLGA-PC NPs capable of loading large amounts of proteins (e.g., ≥ 20 wt%
of NP) to form new polymer-protein complex NPs, utilizing the electrostatic interaction
between proteins and PLGA-PC NPs. The ideal system would require only a simple
formulation method (such as mixing in aqueous solution), while the final complex NPs
would retain a regular spherical shape and size <200 nm (Figures 1 and 4). The desired
structure of the new hybrid NPs would be a nucleus of PLGA-PC NPs surrounded by
proteins, which primarily interact with the PC component of PLGA-PC NPs or other
proteins.
First, a water-soluble L-arginine–based PC library (named as PCx) was developed according
to a modified synthesis protocol (Figure2 and supporting information).21, 22 L-arginine–
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based PCs were chosen because arginine remains positively charged in neutral, acidic, and
even the most basic environments due to the guanidinium group's high pKa (around 12.5),
which enables the PC moiety to interact strongly with the negatively charged proteins and
peptides in aqueous solutions. In Figure 2, by setting monomer molar ratios of I/II< 1.0,
PCs are obtained with NH2 termini (NH2-PC-NH2), which are needed for further
conjugation with PLGA-COOH. To engineer polymeric NPs, di-block copolymers of
PLGA-b-PC were prepared by coupling the carboxy terminal of PLGA and the amino
functionality of PC (Figure 2 and supporting information). The obtained di-block
copolymers of PLGA-b-PC were named PLGAy-PCx (supporting information). Two types
of PLGA-COOH with significantly different MWs were used: PLGA1 (Mn = 43.5 kDa) and
PLGA2 (Mn = 5.0 kDa). The percentage of PLGA-PC cationic moiety, an important factor
for NP protein loading functionality, could be altered by changing the PLGA MW;
decreasing the PLGA MW would increase the cationic moiety density of the copolymer and
the resulting NP.
The nanoprecipitation method was used to produce small, simple PLGA-PC NPs with the
desired core (PLGA)-shell (PC) structure. The particle size and surface charge of PLGA-PC
NPs are very important for the interaction with proteins (discussed in detail below). The
TEM images and DLS results in Figure 3 show that the formed PLGA-PC NPs were mostly
in the range of 20-80 nm, depending on the PLGA-b-PC composition. PLGA MW was the
dominating factor in determining NP size: low-MW PLGA2-based PLGA-PC NPs were
mainly in the size range of 20-40 nm (Figure 3a); while the high-MW PLGA1-based PLGA-
PC NPs were mainly in the size range of 40-80 nm (Figure 3b). Compared to the
corresponding PLGA NPs, the PLGA-PC NPs were smaller (Figure 3d). TEM images in
Figures 3a and 3b demonstrate that the PLGA-PC NPs were spherical or egg shaped, while
the surface morphology was fluffy due to the thick PC shell under dried state in TEM. The
zeta potential of the NPs was in the range of +15 to 50 mv and it was not correlated with
PLGA or PC structure or MW. The cytotoxicity of PLGA-PC NPs was evaluated via an
MTT assay and the NPs were not toxic to either Hela or A549 cells in the concentration
range of 1.0 ng/mL to 200 μg/mL.
Although many strategies have been developed for loading NPs with proteins, serious
challenges remain in easily and rapidly loading a high quantity of proteins into NPs of
reasonably small size in a green manner, i.e., without organic solvents. The PLGA-PC NPs
were designed with these goals in mind. Body charge density, not surface charge, is believed
to determine the protein loading efficiency of a NP in this report. In order to better utilize
the electrostatic field of the thick PC shell to strongly adsorb proteins and form new NP
complexes with the desired size and protein loading capacity, a few formulation strategies
were tried until a very simple method with the lowest contamination was chosen: direct
mixing of aqueous solutions containing PLGA-PC NPs and proteins. Bovine serum albumin
(BSA) was used as a model protein due to its medium size (MW=66.5 kDa) and suitable
charge properties (isoelectric point=4.7). Before the systematic study, a quick experiment
was carried out to verify this proof of concept: simply mixing random amounts of PLGA-PC
NP solutions with BSA solutions. Mixing produces some changes in terms of zeta potential,
particle size, and structure, depending on PLGA-PC type, weight ratio (WR) of PLGA-PC to
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protein, and other formulation conditions. Figure 4a shows a TEM image example of mixing
PLGA2-PC16 NP with 2 wt% BSA in aqueous solution. After mixing, each PLGA-PC NP
was loaded with some proteins on its surface. Some NPs connected through bound proteins,
but the structure of this complex was random and irregular. We then wanted to investigate
the relationships among protein loading efficiency, particle size, structure, and surface
charge of the PLGA-PC NP/BSA complex. We sought to determine whether we could
produce PLGA-PC/BSA complexes with uniform nanostructure, small size, and high protein
loading. To systematically investigate the NP-protein interaction and the structure-function
relationship, two types of PLGA-PC NPs (PLGA1-PC16 and PLGA2-PC16) were selected
and they had very similar structure: the PC blocks were identical, while PLGA blocks had
the same structure but significantly different MWs (43.5kDa and 5.0 kDa, respectively).
Since the MW of PC16 is around 4.5 kDa, the PC composition of PLGA1-PC16 and
PLGA2-PC16 NPs are about 9.4 wt% and 47.4 wt%, respectively. Therefore, the completely
different PC composition (a five-fold difference) made comparison straightforward.
For each PLGA-PC NP system, various PLGA-PC/BSA hybrid complexes were formed by
simply mixing aqueous solutions with a series of desired WRs of PLGA to BSA, ranging
broadly from 5,000 to 2. Figures 4e and 4f show the particle size and zeta potential of
PLGA-PC/BSA particles as a function of the WR of PLGA-PC NP to BSA. In Figures 4e
and 4f, the zeta potential trend of can be divided into four regions. In the first region, as the
WR of PLGA-PC NP to BSA decreased from 5,000 to a few hundred, the zeta potential of
the complex particles also decreased, suggesting that if more proteins were mixed with
PLGA-PC NPs, more of the positively charged surface of the PLGA-PC NP was surrounded
or covered by negatively charged proteins via electrostatic interaction. In the second region,
with more proteins added (WR from a few hundred to a few tens), almost all of the PLGA-
PC NP surface was covered with proteins, and the zeta potential changed from positive to
zero or slightly negative. At this stage, the corresponding WR to the 0 mv zeta potential is
determined by the PC weight percentage. For the third region, a further decrease of the WR
of PLGA-PC NP to protein continued to decrease the zeta potential of the complexed
particle to around -30 mv. For the fourth region, the zeta potential continued to decrease or
plateaued at a value slightly more negative than the zeta potential of pure BSA. The particle
size trend in Figures 4e and 4f can also be divided into the same four regions. In the first
region, as the WR of PLGA-PC to BSA decreased, the size of the complex particle slightly
and steadily increased, suggesting that as more protein was added into the PLGA-PC NP
solutions, the PLGA-PC NPs began to adsorb more proteins on their surface. In the second
region, as the WR of PLGA-PC NP to protein decreased further, the particle size of PLGA-
PC NP/protein complexes significantly increased beyond the expected size range, indicating
some form of connections of NPs. For the largest particle size obtained in this region, the
corresponding zeta potential was around zero. After the second region, however, a
continuing decrease of WR in a narrow range (third region) immediately resulted in a
significant reduction of complex particle size. This phenomenon suggests that the PLGA-PC
NP/protein complex particle may be stable within this narrow WR range and is likely the
optimal formulation. One possible reason for this stable state is that the total positive charge
from PLGA-PC NPs is equal to or close to the total negative charge from BSAs. The small
particle size had a corresponding zeta potential of approximately -20 mv. In this region, the
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PLGA2-PC16 NPs had loaded protein in the range of 15-30 wt% with encapsulation
efficiency over 95%. However, for the PLGA1-PC16 NPs, the corresponding protein-
loading region was in the range of 2-3 wt% due to the low PC density with similar
encapsulation efficiency. In the fourth region, the continuously decreasing WR caused
significant particle size increases, indicating a lack of stable complexes and heavy
aggregation at higher WR of BSA to PLGA-PC NP. These results show that for each type of
PLGA-PC16 NP, the maximum effective loading efficiency was achieved at a small particle
size with a zeta potential range of -10 to -30mv, in a specific and narrow WR range of
PLGA-PC to BSA. Figures 4e and 4f show the same trend for both size and zeta potential,
but different corresponding WR windows for the specific small particle size, suggesting that
this is a function of polymer structure. These relationships hold true for all other developed
PLGA-PC NPs. Briefly, PLGA2-PC NPs have around 10 times the BSA loading capability
of the corresponding PLGA1-PC NPs, and the highest BSA loading with small particle size
always happened in a narrow WR range. When the order of addition was changed
(nanoparticle solution was added into BSA), the complexed particles were larger in the 3rd
region.
Based on the above findings regarding zeta potential and particle size, our findings in the
third region of the PLGA2-PC system were highly interesting: the complexed particles had
small sizes but maintained significant protein loading. TEM was used to study the
complexed particle structure in this region for the PLGA2-PC system. To acquire better
image quality and resolve more details, the formulation protocol was slightly modified
(supporting information) so that NPs with larger size could be obtained without affecting
structure. Figure 4b shows PLGA2-PC/BSA NPs with relatively large size at a WR of 4. It
was surprising to find that all of the new NPs formed by simple mixing were uniform and
spherical complexed NPs. Figure 4d shows a magnified image of two such nanospheres
from Figure 4b. The structure and surface morphology of the complexed NPs were different
from the pure PLGA-PC NPs in Figure 3. Based on the NP size and protein loading amount,
it was predicted that multiple PLGA-PC NPs would be contained in a single complex NP
(size ≥80 nm). Through TEM, the inner structure of some NP complexes was examined,
confirming multiple PLGA-PC NPs inside, acting as nucleus. Figure 4c shows an example
of complexed PLGA2-PC16/BSA, with the size of the internal, smaller PLGA2-PC16 NPs
consistent with those in Figure 3a.
Other proteins/peptides, including ovalbumin, TNF-α, insulin, and Ac2-26 peptide, were
evaluated for interaction with PLGA-PC NPs. The results and relationships were similar to
those found above: complex nanoparticles were formed with PLGA2-PC16 with ≥20 wt%
loading and ≤200 nm size. The MWs of proteins/peptides did not significantly affect
interactions between PLGA-PC NPs and proteins. Additionally, multiple types of proteins
could be loaded simultaneously without making obvious sacrifices in loading efficiency of
each protein (supporting information). The in vitro and in vivo bioactivity of loaded proteins
was evaluated by testing the released TNF-α and insulin, respectively. The results indicated
that this loading strategy did not significantly affect the bioactivity of released proteins
(supporting information). Other types of PLGA-b-PCs with similar MW and PLGA
Wu et al. Page 6
Angew Chem Int Ed Engl. Author manuscript; available in PMC 2015 August 18.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
composition were developed for comparison. NPs around or <50-60 nm formed, but they
could not effectively load large amounts of proteins (supporting information).
The specific complexed PLGA2-PC16/Protein nanospheres formed in the third region were
unstable in buffered solutions. After optimization, it was found that lipid/lipid-PEG (such as
DSPE-PEG(MW≥2,000)) effectively stabilized the negatively charged nanospheres without
causing obvious size change, with only a 5-10 wt% loss in overall protein loading
(supporting information). The stabilization could be due to self-assembly of cationic and
hydrophobic lipid/lipid-PEG on the surface of PLGA2-PC16/protein nanospheres, which
was confirmed by the TEM, the changes of particle size and surface charge and small
protein loss. Figure 5a shows a TEM image of a PLGA2-PC/protein nanosphere coated with
DSPE–PEG3000/Lecithin. Study of the release profile of these nanospheres in PBS buffer
(Figure 5b) revealed some burst release (around 25 wt%) after coating of lipid-PEG and
addition of buffers. Fast release occurred over the first 1-2 days, especially in the initial
hours. After that, release of BSA was sustained and steady for at least three weeks. Finally,
BSAs labeled with red fluorescent dye RITC were loaded to study the cellular interaction of
the PLGA2-PC/Protein nanospheres (supporting information). Figures 5c and 5d show the
cellular uptake of pure RITC-BSA compared to the complex of PLGA2-PC NP/RITC-BSA/
DSPE-PEG3000 after four hours of incubation. After four hours, large numbers of NPs
entered the cells, and the proteins began to be released in a sustained fashion.
In summary, a new PLGA-PC NP platform with a core-shell structure and a new “green”
protein-loading strategy were developed and evaluated for protein delivery as well as
structure–function relationships. Two issues were investigated: 1) the effect of PLGA-PC
structure on the resulting NP structure and protein encapsulation capability, and 2) the
relationship between the size of PLGA-PC/Protein NPs, their zeta potential, and protein
loading efficiency. The results indicated that PLGA-PC polymer structure primarily dictates
NP size and interaction with proteins. And the particle size, zeta potential, and weight ratio
of PLGA-PC NP/Protein are closely related. Some screened PLGA-PC NPs were able to
interact with proteins, forming new multi-nuclear spherical NPs with high protein loading
(20-40 wt%) and 100-200 nm size by simple mixing in aqueous solutions. These findings
could facilitate the development of new robust protein-delivery platforms or the
modification of currently existing platforms for green protein loading.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Illustration of the synthesis of PLGA-b-polycation (PC) copolymer, PLGA-PC NP, PLGA-
PC/Protein NP, PLGA-PC/Protein/Lipid-PEG NP, and the multinuclear structure of NP.
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Figure 2.
Synthesis of L-arginine–based PC (1) and PLGA-b-PC copolymer (2)
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Figure 3.
TEM images of PLGA-PC NPs (a)PLGA2-PC16; (b) PLGA1-PC16; (c) illustration of
PLGA-PC composition effect (by changing PLGA portion) on nanoparticle size; (d) Particle
size of PLGA-PC and PLGA NPs from DLS.
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Figure 4.
TEM images of PLGA-PC/Protein nanoparticles (a-d): (a) PLGA2-PC 16 with 2 wt% BSA
loading; (b-d) PLGA2-PC16 with 25 wt% BSA loading. Structure-function relationship
among the zeta potential, particle size, and weight ratio of PLGA-PC/BSA complex particle
(e-f)
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Figure 5.
(A) and (B), TEM image and release profile of PLGA2-PC16 NP/BSA/DSPE–PEG3000;
(C) and (D), the cellular uptake of fluorescence BSA (c) and PLGA2-PC16 NP/fluorescence
BSA / DSPE–PEG3000 (d) after 4 hours.
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